Summary:
- The FDA has approved a new obesity medication called Orforglipron, developed by pharmaceutical company Eli Lilly.
- Orforglipron works by targeting specific hormones and pathways in the body to suppress appetite and increase metabolism, leading to significant weight loss in clinical trials.
- This approval represents an important advancement in the treatment of obesity, a growing public health concern, and provides a new option for individuals struggling with weight management.